Norway· NO-ID_9FB1455D-C457-405C-BB9D-BA39E2B629A4
Triumeq
A lamivudine, abacavir and dolutegravir product containing abacavir + lamivudine + dolutegravir, registered in Norway by ViiV Healthcare BV (1). The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Lamivudine, abacavir and dolutegravir is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AR13 (lamivudine, abacavir and dolutegravir), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Lamivudine, abacavir and dolutegravir · ATC J05AR13
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Abacavir + Lamivudine + Dolutegravir
- Manufacturer
- ViiV Healthcare BV (1)
- Country
- Norway (NO)
- ATC code
- J05AR13
- ATC class
- Lamivudine, abacavir and dolutegravir
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_9FB1455D-C457-405C-BB9D-BA39E2B629A4
- no_varenummer56925730NOK 10762
- gtin5054626151115
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for lamivudine, abacavir and dolutegravir.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lamivudine, abacavir and dolutegravir · interactions on record
2 records
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Lamivudine, abacavir and dolutegravir in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandTriumeqViiV Healthcare BV
- CzechiaTRIUMEQViiV Healthcare BV, Amersfoort
- SpainTRIUMEQ 5 MG/60 MG/30 MG COMPRIMIDOS DISPERSABLESViiv Healthcare B.V.
- FranceTRIUMEQ 5 mg/60 mg/30 mg, comprimé dispersibleVIIV HEALTHCARE (PAYS-BAS)
- United KingdomTriumeq 50mg/600mg/300mg tabletsViiV Healthcare UK Ltd
- IrelandTriumeq 5 mg/60 mg/30 mg dispersible tabletsViiV Healthcare BV
- IcelandTriumeqViiV Healthcare BV
- NetherlandsTriumeq 5 mg/ 60 mg/ 30 mg dispergeerbare tablettenViiV Healthcare B.V.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Iceland · Triumeq
- Liechtenstein · Triumeq
- Malta · Dolutegravir/Abacavir/Lamivudine Pharos
- Portugal · Dolutegravir/Abacavir/Lamivudine Pharos
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/94555d4c-d0bd-4e71-bc73-dfbbca950e7f GET /v1/drugs/94555d4c-d0bd-4e71-bc73-dfbbca950e7f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett, filmdrasjert",
"source": "fest",
"status": "A",
"atc_name": "Lamivudin, abakavir og dolutegravir",
"merkevare_id": "ID_9FB1455D-C457-405C-BB9D-BA39E2B629A4",
"name_form_strength": "Triumeq tab 50 mg/600 mg/300 mg",
"prescription_group": "C"
}See everything about lamivudine, abacavir and dolutegravir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.